Rakshi J S, Pavese N, Uema T, Ito K, Morrish P K, Bailey D L, Brooks D J
MRC Clinical Sciences Centre Imperial College School of Medicine, Hammersmith Hospital, London, UK.
J Neural Transm (Vienna). 2002 Dec;109(12):1433-43. doi: 10.1007/s00702-002-0753-0.
To study the relative rates of progression of early Parkinson's disease (PD) in patients started on a dopamine agonist, ropinirole, or L-dopa.
A double-blind study of 45 early PD patients [mean age 61 +/- 9.8 SD and mean symptom duration, 26 +/- 16 SD months] randomized 2 : 1 (ropinirole : L-dopa). Supplementary L-dopa was allowed if, during the trial, there was lack of a therapeutic effect. (18)F-dopa PET scans were performed at baseline (n = 45) and 2 years (n = 37).
At two years, the mean percentage reduction in putamen (18)F-dopa uptake (Ki(o)) was not significantly different between the two groups (13% ropinirole, n = 28 versus 18% L-dopa, n = 9).
We found no significant overall difference in underlying PD progression, after two years treatment, between patients groups. In summary, (18)F-dopa PET can be employed to objectively evaluate the effect of potential neuroprotective agents on dopaminergic function.
研究起始使用多巴胺激动剂罗匹尼罗或左旋多巴的早期帕金森病（PD）患者的相对进展率。
对45例早期PD患者[平均年龄61±9.8标准差，平均症状持续时间26±16标准差月]进行双盲研究，按2:1随机分组（罗匹尼罗：左旋多巴）。如果在试验期间缺乏治疗效果，则允许补充左旋多巴。在基线时（n = 45）和2年时（n = 37）进行（18）F - 多巴PET扫描。
两年时，两组间壳核（18）F - 多巴摄取量（Ki（o））的平均降低百分比无显著差异（罗匹尼罗组为13%，n = 28；左旋多巴组为18%，n = 9）。
我们发现，两组患者经过两年治疗后，潜在的PD进展无显著总体差异。总之，（18）F - 多巴PET可用于客观评估潜在神经保护剂对多巴胺能功能的影响。
Zotero 插件